Preventing Biofilm Formation and Encrustation on Urinary Implants: (Bio)coatings and Tissue Engineering
Author:
Buchholz Noor,de Graaf Petra,de la Cruz Julia E.,Kram Wolfgang,Skovorodkin Ilya,Soria Federico,Vainio Seppo
Abstract
AbstractEven though urinary stents and catheters have been commonly applied in medicine for several decades and still are constantly being modified and optimized, their structure and performance still requires further improvement. A major drawback of urinary implants is the deposition of organic and non-organic substances on their surface leading to biofilm formation resulting in encrustations, blockages, and infections. Promising research lines are stent coatings with antibodies, enzymes and various bioactive compounds. We will also discuss the possibility of making urinary implants more “tissue friendly” by designing biomimetic surfaces. Finally, in accordance with the paradigm “repair or regrow” we will touch on tissue engineering approaches to replace artificial urinary implants by those generated in vitro or in vivo from homologous tissue. We summarised modern biological approaches to improve the structure, function and performance of urinary stents. Some have been already applied in urinary stent production whilst others have been tested in the field of vascular stents, such as antibody or biomimetic coating. Bioengineering approaches aiming at the generation of complete analogs of damaged urinary tissue from autologous patient-derived cells represent a more futuristic outlook. Nevertheless, we hope that the rapid development of advanced multidisciplinary research platforms in modern biomedicine will make these approaches feasible in the near future.
Publisher
Springer International Publishing
Reference38 articles.
1. Wawrzyńska M, Duda M, Wysokińska E, Strządała L, Biały D, Ulatowska-Jarża A, Kałas W, Kraszewski S, Pasławski R, Biernat P, Pasławska U, Zielonka A, Podbielska H, Kopaczyńska M. Functionalized CD133 antibody coated stent surface simultaneously promotes EPCs adhesion and inhibits smooth muscle cell proliferation—a novel approach to prevent in-stent restenosis. Colloids Surf B Biointerfaces. 2019;174(1):587–97. 2. Wawrzyńska M, Kraskiewicz H, Paprocka M, Krawczenko A, Bielawska-Pohl A, Biały D, Roleder T, Wojakowski W, O'Connor IB, Duda M, Michal R, Wasyluk Ł, Plesch G, Podbielska H, Kopaczyńska M, Wall JG. Functionalization with a VEGFR2-binding antibody fragment leads to enhanced endothelialization of a cardiovascular stent in vitro and in vivo. J Biomed Mater Res B Appl Biomater. 2020;108(1):213–24. 3. de Winter RJ, Chandrasekhar J, Kalkman DN, Aquino MB, Woudstra P, Beijk MA, Sartori S, Baber U, Tijssen JG, Koch KT, Dangas GD, Colombo A, Mehran R, MASCOT; REMEDEE Registry Investigators. 1-Year clinical outcomes of all-comer patients treated with the dual-therapy COMBO stent: primary results of the COMBO Collaboration. JACC Cardiovasc Interv. 2018;11(19):1969–78. 4. Cui S, Liu JH, Song XT, Ma GL, Du BJ, Lv SZ, Meng LJ, Gao QS, Li K. A novel stent coated with antibodies to endoglin inhibits neointimal formation of porcine coronary arteries. Biomed Res Int. 2014;2014:428619. 5. Lim KS, Jeong MH, Bae IH, Park JK, Park DS, Kim JM, Kim JH, Kim HS, Kim YS, Jeong HY, Song SJ, Yang EJ, Cho DL, Sim DS, Park KH, Hong YJ, Ahn Y. Effect of polymer-free TiO2 stent coated with abciximab or alpha lipoic acid in porcine coronary restenosis model. J Cardiol. 2014;64(5):409–18.
|
|